Inclusion Criteria:  Age of ≥ 18 years old; ECOG PS score of 0 or 1; Pathologically diagnosed as prostate adenocarcinoma; High-risk patients No distant metastasis (clinical staging of M0) as determined by BICR of imaging examinations; Subjects who are candidates for and plan to undergo radical prostatectomy (removal of the entire prostate and seminal vesicle plus pelvic lymphadenectomy);  Exclusion Criteria:  Subjects who received any prior treatment for prostate cancer, except medical ADT and/or first-generation androgen receptor antagonists (such as bicalutamide) for not more than 4 weeks; Subjects who received any other investigational products or underwent major surgery within 4 weeks prior to randomization; Subjects who are planning bilateral orchidectomy during the treatment period of the study; Subjects with dysphagia, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake and absorption; Subjects with a history of epilepsy, or diseases that can induce seizures occurred within 12 months prior to randomization (including a history of transient ischemic attack, stroke, traumatic brain injury, and cognitive impairment, requiring hospitalization); Subjects with active heart disease within 6 months prior to randomization, including: severe/unstable angina pectoris, myocardial infarction, symptomatic congestive heart failure, and ventricular arrhythmias requiring medical treatment;